Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).
Epistemonikos ID: d5179a1419b880b08a6e229a311a46362d4b455d
First added on: May 14, 2024